INOCOR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INOCOR is an injectable small-molecule NDA approved in 1984 by Sanofi. The indication and mechanism of action are not publicly specified in available data. This is a mature, legacy product approaching loss of exclusivity.
LOE Approaching
This product is in terminal lifecycle phase with minimal headcount expansion expected; roles are likely focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Assess the Efficacy and Safety of Rhinocort Aqua
Started Apr 2004
650 enrolled
Allergic Rhinitis
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
Started Apr 2003
750 enrolled
Seasonal Allergic Rhinitis
Career Relevance
Working on INOCOR offers limited career growth; this is a sunset assignment suited to consolidating market share or managing generic transition. Opportunities are primarily in sales operations and supply chain rather than strategic brand-building.
Brand Manager
Worked on INOCOR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.